Lantern Pharma/$LTRN

1D1W1MYTD1Y5YMAX

About Lantern Pharma

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Ticker
$LTRN
Sector
Health
Primary listing
NASDAQ
Employees
16
Headquarters
Dallas, United States
Website
www.lanternpharma.com

Lantern Pharma Metrics

BasicAdvanced
$20M
-
-$1.63
2.33
-

Lantern Pharma News

AllArticlesVideos

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire1 month ago

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Business Wire2 months ago

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.